Physician profile
John Albert Mitchell
NPI 1205886124
$9,568.14
in general payments reported to CMS, 2019-2025
42 companies · $2,109 in 2025
The $2,109 reported for 2025 was more than what 87% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $239 · 2021: $1,128 · 2022: $1,615 · 2023: $2,073 · 2024: $2,041 · 2025: $2,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,205 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,204.91 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,539.92 | 2020-2025 | Fasenra, Tezspire, Airsupra |
| Jazz Pharmaceuticals INC. | $1,073.79 | 2019-2025 | |
| Glaxosmithkline, LLC. | $992.10 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $723.20 | 2019-2025 | Arikayce, Brinsupri |
| Axsome Therapeutics, INC. | $526.82 | 2023-2025 | Sunosi |
| Genzyme Corporation | $442.56 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $402.71 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $396.14 | 2020-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.07 | 2019-2025 | Ofev, Jardiance, Jascayd |
| Harmony Biosciences LLC | $343.44 | 2020-2025 | Wakix |
| Mylan Specialty L.P. | $318.19 | 2019-2024 | Yupelri |
| Amgen INC. | $306.28 | 2021-2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $264.48 | 2022-2025 | Acthar |
| United Therapeutics Corporation | $215.83 | 2023-2025 | Tyvaso, Tyvaso |
| Philips North America LLC | $176.20 | 2021-2025 | Vest Therapy Und |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $148.72 | 2023-2025 | Glassia, Hyqvia |
| Merck Sharp & Dohme LLC | $145.83 | 2023-2025 | Winrevair, Zerbaxa, Keytruda |
| Verona Pharma, INC. | $118.31 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $103.86 | 2024-2025 | Lumryz |
| Inspire Medical Systems, INC. | $98.36 | 2024-2025 | Inspire |
| Baxter Healthcare | $84.46 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Inari Medical, INC. | $83.70 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $72.60 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $66.13 | 2022-2023 | Airduo Digihaler |
| Lilly USA, LLC | $59.45 | 2025 | Zepbound, Mounjaro |
| Inogen, INC. | $58.30 | 2022-2024 | |
| Abbvie INC. | $57.89 | 2021-2024 | |
| Genentech USA, INC. | $45.45 | 2023 | Xolair |
| Resmed Corp | $43.18 | 2021 | |
| Viatris Specialty LLC | $37.63 | 2025 | Yupelri |
| Shionogi INC | $31.48 | 2022 | |
| Eisai INC. | $29.24 | 2021 | |
| Electromed, INC. | $27.66 | 2025 | Smartvest |
| Idorsia Pharmaceuticals US INC | $18.59 | 2024 | Quviviq |
| Medtronic, INC. | $18.55 | 2024 | Illumisite |
| Csl Behring | $18.43 | 2020 | |
| Gilead Sciences, INC. | $16.65 | 2023 | |
| Paratek Pharmaceuticals, INC. | $16.35 | 2023 | Nuzyra |
| Alexion Pharmaceuticals, INC. | $15.47 | 2021 | |
| Grifols USA, LLC | $14.03 | 2022 | |
| Optinose US, INC. | $12.77 | 2021 | |
| Advanced Respiratory, INC | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.